Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rhone-Poulenc Rorer

This article was originally published in The Tan Sheet

Executive Summary

Rhone-Poulenc Fibers and Polymers CEO Michel de Rosen appointed to RPR president and chief operating officer under the company's succession plan for departing RPR Pharmaceuticals President Randy Thurman. In addition, de Rosen will assume the responsibilities of RPR's Office of the President, which was set up during the merger of Rhone-Poulenc and Rorer three years ago and was headed by Thurman and Jean-Jacques Bertrand, president of RPR S.A. Thurman has accepted a position with Corning Labs as chairman and CEO of that company's Metpath/Damon Labs operations and will sit on Corning's board for pharmaceutical and environmental businesses. Bertrand will assume the title of vice chairman and CEO of Pasteur Merieux Serums and Vaccines, effective Jan. 1, 1994. The current CEO of Pasteur Merieux, Alain Audubert, will be promoted to a new position in RPR at the start of 1994.
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081908

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel